Author: admin

The Coronary Stents Market to Reach $12.93 Billion by 2029, Strategic Acquisitions & New Product Launches Shape the Future of the Market – Arizton

“Coronary Stents Market Research Report by Arizton”

According to the latest research report, the global coronary stents market by Arizton Advisory & Intelligence, will grow at a CAGR of 7.10% during 2023-2029. 

 

Curious to Learn More? Click: https://www.arizton.com/market-reports/coronary-stents-market-analysis-2024 

 

Report Summary 

Market Size (2029): $12.93 Billion 

Market Size (2023): $8.57 Billion 

CAGR (2023-2029): 7.10% 

Historic Year: 2020-2022 

Base Year: 2023 

Forecast Year: 2024-2029 

Market Segmentation: Product, Design, End-User and Geography 

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa 

 

Stay ahead of the curve with Arizton’s exclusive subscription plan, offering in-depth analysis, market sizing, and growth forecasts for less than $900 per month—a significant value compared to individual report purchases. Click here: https://www.arizton.com/subscription       

 

The global coronary stents market is characterized by intense competition and dynamism, with numerous national, regional, and global players. Strict and varied regulatory norms, pricing policies, and approval processes contribute to the competitive landscape. Market growth is driven by the increasing burden of cardiovascular diseases, a rising geriatric population with multiple chronic conditions, and heightened attention to coronary artery disease management through stenting and angioplasty. Continuous product development, launches, and approvals are revolutionizing the market, enhancing access to safe coronary stenting, and expected to sustain market growth in the future. 

 

Market Trends & Drivers 

Evolving Coronary Stent Technologies 

Coronary stent implantation is a globally accepted treatment for coronary artery disease (CAD). The market is evolving from bare metal and drug-eluting stents to more advanced bioresorbable and polymer-free stents. Emerging alternatives such as gene eluting stents (GES) and customized stents with self-reporting sensors are also gaining traction. Customized coronary stent sensors developed through novel 4D printing technologies are expected to drive future advancements. New approaches, including biodegradable polymer-coated stents, polymer-free stents (drug-eluting), and bioresorbable stents, have significant potential to transform the market. The benefits of biodegradable polymer-coated stents include improved prevention of acute occlusion or recoil, avoidance of late vessel wall inflammation, and reduced neointimal hyperplasia. 

Advances in Coronary Stent Fabrication 

Traditional fabrication methods for coronary stents, such as laser cutting, are being enhanced with advanced technologies like augmented reality (AR), 3D printing, and deep learning (DL). Novel 4D digital printing technologies are enabling the production of coronary stents that are significantly smaller and more customized to patient needs. These technologies employ stimuli-responsive materials to create implants tailored to an individual’s physiological and pathological conditions. Smart stents with biocompatible platforms, including small ultrasound transducers to measure blood flow, are also being explored. These advancements are expected to revolutionize the market by reducing inflammation, fibrous tissue formation, and material degradation. 

Increasing Burden of Cardiovascular Disorders 

Cardiovascular diseases (CVD) continue to be a leading cause of mortality worldwide, with over 620 million people suffering from circulatory and heart diseases in 2023. Coronary artery disease remains a major CVD condition, demanding significant healthcare resources. The prevalence of stroke is also rising, particularly in developing countries. Each year, over 60 million people are diagnosed with circulatory and heart diseases, contributing to a significant mortality burden, with 20 million deaths reported in 2021. By 2024, it is estimated that 244 million people will be affected by coronary artery disease, with 6 million patients undergoing various coronary interventions annually. 

 

North America Leading the Global Coronary Stents Market 

In 2023, North America held over 38% of the global coronary stents market, leading the industry with a projected CAGR of 5.26% during the forecast period. The US and Canada contributed 90.71% and 9.29% to the market share, respectively. The dominance of the US is due to its high volume of percutaneous coronary interventions (PCI), a large patient population needing cardiovascular disease (CVD) management, and substantial healthcare spending on coronary artery disease (CAD) and related conditions like diabetes. 

According to the CDC, around 400,000 people in North America died from coronary heart diseases in 2022. In 2021, CAD affected 1 in 18 adults aged 20 and above, with a 10% prevalence rate. Approximately 895,000 heart disease-related deaths occurred in 2021, with heart diseases costing the region $245 billion annually. 

Market growth is driven by the aging population, increasing chronic disease cases, heightened heart health awareness, rising healthcare expenditure, and improvements in healthcare facilities. The region has 33 million registered diabetes cases, many of which are linked to heart diseases requiring coronary stents. 

Key vendors like Abbott and Boston Scientific Corporation dominate the market, contributing to over 500,000 coronary stent implantations annually in the US alone. The presence of numerous vendors and their increasing market penetration intensifies price competition. 

 

Recent Vendor Activities 

  • In 2023, Abbott acquired Cardiovascular Systems, a medical device company that manufactures an advanced atherectomy system for treating coronary and peripheral artery disease. 

  • In 2023, Translumina, a global company in interventional cardiovascular medical devices, acquired Blue Medical Devices, a Wellinq Group Company. This acquisition supports and strengthens Translumina’s drug-eluting stents portfolio. 

  • In 2022, MicroPort established its new headquarters in Irvine, which has facilities such as a manufacturing plant and innovation center. 

  • In April 2022, Biosensor International Group received Japanese PMDA approval for its BioFreedom Ultra and US FDA approval for BioFreedom coronary stents. 

 

Recent Product Launches 

  • In December 2023, Terumo (India) launched a drug-eluting stent for the treatment of coronary artery disease, Ultimaster Nagomi. 

  • In Aug 2022, Medtronic launched a newly developed drug-eluting stent, Onyx Frontier coronary stent, with CE market approval. 

 

Buy this Report @ https://www.arizton.com/market-reports/coronary-stents-market-analysis-2024 

 

Key Vendors 

  • Abbott 

  • Boston Scientific Corporation 

  • Medtronic 

  • Biotronik 

  • TerumoCorporation 

  • B.Braun SE 

  • Biosensors International Group 

  • MicroPort Scientific Corporation 

  • Alvimedica 

  • Vascular Concepts 

  • Balton 

  • Cardionovum 

  • Cook Medical 

  • Concept Medical 

  • Relisys Medical Devices 

  • Elixir Medical 

  • Endocor GmBH 

  • OrbusNeich Medical Group 

  • Eurocor Tech 

  • HEXACATH 

  • InSitu Technologies 

  • Lepu Medical Technology 

  • Medinol 

  • Meril Life Sciences 

  • Q3 Medical Devices 

  • REVA Medical, LLC 

  • S3V Vascular Technologies 

  • Sahajanand Medical Technologies 

  • SCITECH 

  • Translumina 

  • USM Healthcare 

  • Minvasys 

 

Segmentation & Forecast 

  • Product Type 

  • Drug-eluting Stents (DES) 

  • Second Generation 

  • Latest Generation 

  • Bare Metal Stents 

  • Bioresorbable Stents 

  • Design 

  • Permanent 

  • Fully Degradable 

  • End-user 

  • Multi-specialty Hospitals 

  • Specialty Hospitals 

  • Geography 

  • North America 

  • The U.S. 

  • Canada 

  • Europe 

  • Germany 

  • The U.K. 

  • France 

  • Italy 

  • Spain 

  • APAC 

  • Japan 

  • China 

  • India 

  • Australia 

  • South Korea 

  • Latin America 

  • Brazil 

  • Mexico 

  • Argentina 

  • Middle East & Africa 

  • Turkey 

  • South Africa 

  • Saudi Arabia 

 

Key Questions Answered in the Report: 

How big is the global coronary stents market? 

What is the growth rate of the global coronary stents market? 

Who are the major players in the global coronary stents market? 

Which region dominates the global coronary stents market? 

What are the key drivers of the global coronary stents market? 

 

Check Out Some of the Top Selling Reports of Your Interest:    

Fractional Flow Reserve Market – Global Outlook & Forecast 2024-2029 

https://www.arizton.com/market-reports/fractional-flow-reserve-market 

U.S. Picture Archiving & Communication System (PACS) Market – Focused Insights 2024-2029 

https://www.arizton.com/market-reports/us-picture-archiving-and-communication-system-market 

 

Why Arizton?                               

100% Customer Satisfaction                               

24×7 availability – we are always there when you need us                               

200+ Fortune 500 Companies trust Arizton’s report                               

80% of our reports are exclusive and first in the industry                               

100% more data and analysis                               

1500+ reports published till date             

 

Post-Purchase Benefit                           

1hr of free analyst discussion                           

10% off on customization        

 

About Us:                                                                    

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                  

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                   

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                         

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707       
Country: United States
Website: https://www.arizton.com/market-reports/coronary-stents-market-analysis-2024

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Coronary Stents Market to Reach $12.93 Billion by 2029, Strategic Acquisitions & New Product Launches Shape the Future of the Market – Arizton

Excelion Development Group Launches Exciting Investment Opportunity in the Real Estate Market Through its €250 Million Property Portfolio

This groundbreaking investment to, now listed on the capital platform is going to cater to the wealth creation, income generation, and diversification needs of investors and prospects in the United Kingdom

Excelion Development Group, a leading real estate investment company, is thrilled to announce its strategic partnership and launch of a €250 million property portfolio on Capital Platform. This opportunity is going to provide unique channels through which UK investors and expats looking for attractive avenues to grow their wealth and diversify their income to do so seamlessly.

Under the guidance of Excelion Development Group, this exclusive investment opportunity focuses on alternative investments, providing a diverse portfolio for investors looking to diversify their assets. With a keen focus on attracting individuals with a significant amount of capital and those working in the financial sector in London, such as pensions firms, investment firms, and wealth managers, Excelion Development Group aims to provide a secure and lucrative investment option.

Investors can expect a range of benefits from this investment opportunity, including potential long-term growth, regular passive income, and access to alternative investment options with a proven track record. Excelion Development Group’s team of experienced professionals ensures that all investment options are thoroughly vetted, removing any red flags or potential risks.

For individuals looking to diversify their investment portfolio, Excelion Development Group’s new offering on CapitalPlatform.co.uk presents an opportunity to access alternative investments with lucrative returns. Whether one is a self-certified investor, a high-net-worth individual, a professional in the financial sector, or an expat seeking stable passive income, Excelion Development Group is dedicated to providing a secure and rewarding investment experience.

The company leverages its extensive experience to craft exceptional real estate opportunities that consistently align with investor and client aspirations. With an unwavering commitment to excellence, Excelion Dev ensures a harmonious balance between profitability and client satisfaction, solidifying its position as an industry leader.

Visit www.exceliondev.com to learn more about this all-new investment opportunity.

About Excelion Development Group

Excelion Development Group’s journey commenced 15 years ago when it emerged as a humble real estate company in Belgium, specializing in the renovation and sale of modest houses.

With an unwavering dedication to excellence and a deep comprehension of the ever-evolving market dynamics, Excelion has evolved into a prominent player in the international real estate arena.

The company’s relentless pursuit of growth and unwavering commitment to investor success have propelled it to new heights, especially in the post-pandemic era. This exceptional achievement stands as a testament to its strategic foresight and adeptness in navigating market shifts.

For more information, please visit https://exceliondev.com/about/.

Disclaimer: This press release may contain forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies (including product offerings, regulatory plans and business plans) and may change without notice. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements.

Media Contact
Company Name: Capital Platform
Contact Person: Adam Lawson
Email: Send Email
Phone: 02033550570
Country: United Kingdom
Website: www.capitalplatform.co.uk

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Excelion Development Group Launches Exciting Investment Opportunity in the Real Estate Market Through its €250 Million Property Portfolio

The Itzhak Zarug Collection, the World’s Finest and Largest Holding of Russian Art, continues to mesmerize the world

Itzhak Zarug continues to be a prominent figure in the art world today.

In the late 1920s and early 1930s, the Soviet Union under the Bolsheviks enforced strict controls over cultural expressions, holding the abstract and avant-garde art, which they viewed as elitist and subversive. Such art was perceived as menacing to the new social order because it did not conform to the straightforward, apostle art that the regime favored. As such, thousands of paintings by prominent Russian artists like Wassily Kandinsky, Kazimir Malevich, and Marc Chagall were grasped and stored in museums across Russia, often hidden, neglected, or poorly preserved, to suppress their influence on society.

In the early 1990s, following the dissolution of the Soviet Union, Russia faced severe economic turmoil and was on the brink of bankruptcy. The government was desperate to raise funds to stabilize the economy and provide basic services. As part of their efforts to generate revenue, they began to liquidate various state-owned assets, including real estate, hotels, and valuable artworks. Western art dealers and collectors were quick to seize this opportunity, often purchasing these valuable pieces at liquidation prices far below their market value.

A major buyer was Itzhak Zarug, who bought over 2000 paintings. Zarug emerged as a significant figure in the art market during the post-Soviet economic crisis. Recognizing the opportunity presented by Russia’s need to raise funds quickly, he acquired several valuable artworks at relatively low prices. Unlike some who might have sold the artworks for a quick profit, Zarug is noted for his efforts to preserve and promote Russian art. He often loaned pieces from his collection to museums and exhibitions, helping to raise awareness and appreciation of these works globally.

Itzhak Zarug became particularly active in the art market between 1990 and 2010, slowly selling the paintings at auctions at moderate prices. Zarug’s business was doing well until controversy arose in 2013 when he was accused of selling fake paintings. Zarug was sent to prison whilst in Germany and all 1,800 of his paintings were seized. However, after 3 and a half years of investigations and many experts authenticating the paintings, his paintings were all discovered legitimate. In 2018, all Zarug collections were found authentic and he could resume selling his paintings as he pleased.

Itzhak Zarug continues to be a prominent figure in the art world today. His efforts promote appreciation for art for its beauty, aesthetics, and craftsmanship and displays how art is a means to foster dialogue, bridge cultural gaps, and promote understanding between people of different backgrounds. The art world was always meant to help preserve and transmit the traditions and stories from these paintings—and Zarug has always strived to support this mission.

For more information, visit Itzhak Zarug at: https://www.facebook.com/itzhak.zarug/

Media Contact
Company Name: Alain. Wundermann
Contact Person: Mr. Alain. Wundermann
Email: Send Email
City: Paris
Country: France
Website: https://www.facebook.com/itzhak.zarug/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Itzhak Zarug Collection, the World’s Finest and Largest Holding of Russian Art, continues to mesmerize the world

Breast Imaging Market worth $6.6 billion by 2028

“In the near future, the breast imaging industry is poised for significant advancements driven by technological innovations and evolving healthcare needs. Enhanced imaging technologies like digital breast tomosynthesis, molecular breast imaging, and contrast-enhanced mammography will improve detection accuracy and enable early diagnosis.”
Browse 244 market data Tables and 37 Figures spread through 276 Pages and in-depth TOC on “Breast Imaging Market by Technology (Ionizing, Non-ionizing), Product (Breast Imaging Systems, Software and Services, Accessories), End User (Hospitals and Clinics, Diagnostic Imaging Centers, Breast Care Centers) – Global Forecasts to 2028

Breast Imaging Market in terms of revenue was estimated to be worth $4.4 billion in 2023 and is poised to reach $6.6 billion by 2028, growing at a CAGR of 8.5% from 2023 to 2028 according to a new report by MarketsandMarkets™. The major factors driving the growth of this market include rising awareness campaigns, increasing public-private investments, and lucrative opportunities in emerging markets.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=897

 

Non-ionizing breast imaging technologies segment to register significant growth rate over the forecast period of 2023-2028

Based on the technology, the global breast imaging market is segmented into ionizing breast imaging technologies and non-ionizing breast imaging technologies. The non-ionizing breast imaging technologies segment is anticipated to register the highest growth rate over the forecast period. The ionizing breast imaging technologies segment accounted for the highest share of the breast imaging market in 2022.

Software & services segment accounted for the largest share of the breast imaging market, by product in 2022.

Based on product, the global breast imaging market is segmented into breast imaging systems, software & services, and accessories. Software & services segment accounted for the largest share of the market in 2022 and is expected to grow at the highest CAGR during the forecast period.

Factors such as the rising installation in end user facilities and introduction of novel software drive the growth of the market.

The hospitals and clinics segment accounted for the largest share of the breast imaging market, by end user, in 2022

Based on end user, the global breast imaging market is segmented into hospitals and clinics, diagnostic imaging centers, breast care centers, and other end users. The hospitals and clinics segment accounted for the largest share of the market in 2022. Consistent rise in the adoption of advanced instruments supporting early detection by different end users are driving the growth of this segment.

The Asia Pacific market to register the highest growth in the market during the forecast period

The Asia Pacific breast imaging market is anticipated to register the highest growth from 2023 to 2028. Major players in the market are focusing on expanding their manufacturing capabilities in the APAC. This region is consistently witnessing a rise in the adoption of high-end equipment, offering significant growth opportunities for the key players.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=897

Breast Imaging Market Dynamics:

Drivers:

  1. Rising incidence of breast cancer

Restraints:

  1. High equipment costs

Opportunities:

  1. Growth potential in emerging countries

Challenges:

  1. Errors in breast cancer screening

Key Market Players:

As of 2022, prominent players in the breast imaging market are GE Healthcare (US), Hologic, Inc. (US), Siemens Healthcare GmbH (Germany), Koninklijke Philips N.V. (Netherlands), and FUJIFILM Holdings Corporation (Japan).

Recent Developments:

  • In 2021, Hologic launched a new ultrasound system, SuperSonic MACH 20. This system enhances diagnostic accuracy as well as efficiency. It provides users with improved image quality along with innovative imaging modes.
  • In 2020, GE HealthCare introduced the industry’s first contrast-enhanced guided biopsy solution for breast cancer patients. Serena Bright enables clinicians to access contrast guidance for conducting breast biopsy exams using the same mammography equipment.
  • In 2022, Siemens Healthcare GmbH expanded its ultrasound portfolio by launching refreshed Acuson family systems. These systems have enhanced clinical adaptability and can be used for routine purposes.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=897

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/breast-imaging-technologies-market-897.html

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Breast Imaging Market worth $6.6 billion by 2028

Neuroendocrine Tumors Pipeline 2024 | Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene

DelveInsight’s, “Neuroendocrine Tumors Pipeline Insight 2024” report provides comprehensive insights about 115+ companies and 130+ pipeline drugs in Neuroendocrine Tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Neuroendocrine Tumors therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Neuroendocrine Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Neuroendocrine Tumors Pipeline Outlook

 

Key Takeaways from the Neuroendocrine Tumors Pipeline Report

  • July 2024:- Georgiamune Inc– A Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination With Anti-PD-1 in Advanced Solid Tumors. GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
  • July 2024:- UNICANCER– Dostarlimab as First-line Treatment for Patients With dMMR/MSI (Non-colorectal/Non-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression.
  • July 2024:- Merck Sharp & Dohme LLC- A Phase I/II Study of Pembrolizumab (MK-3475) in Children With Advanced Melanoma or a PD-L1 Positive Advanced, Relapsed or Refractory Solid Tumor or Lymphoma (KEYNOTE-051). Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at least 1 of the types of cancer to get smaller or go away.
  • DelveInsight’s Neuroendocrine Tumors Pipeline analysis depicts a robust space with 115+ active players working to develop 130+ pipeline treatment therapies.
  • The leading Neuroendocrine Tumors Companies such as Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene, Camurus, EpicentRx, RayzeBio, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Vyriad, Inc. and others.
  • Promising Neuroendocrine Tumors Therapies such as Ipilimumab, Nivolumab, Pembrolizumab, Niraparib, Apalutamide, Selpercatinib, Cabozantinib, Vandetanib, and others.

 

Stay ahead with the most recent pipeline outlook for Neuroendocrine Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Neuroendocrine Tumors Approved Drugs

 

Neuroendocrine Tumors Emerging Drugs

  • RYZ101: RayzeBio, Inc.

RYZ101 is an investigational, targeted RPT designed to deliver a highly potent alpha-emitting radioisotope, Actinium-225 (Ac225), to solid tumors expressing SSTR2. RYZ101 leverages DOTATATE, a known binder and linker used in other radiopharmaceutical produts. RYZ101 uses Ac225 instead of the Lu177 used in Lutathera and thus delivers hundreds of times more potency in cancer cell killing. The higher potency of RYZ101 can provide significant clinical benefit to patients. RYZ101 utilizes a proprietary and patent protected formulation. The drug is being developed for gastroenteropancreatic neuroendocrine tumor, pancreatic net, neuroendocrine tumors, extensive stage small cell lung cancer (ES-SCLC), and other tumors.

  • SVV-001: Seneca Therapeutics

SVV-001, an oncolytic virus of the genus Seneca in the Picornaviridae family. SVV-001 is characterized by its ability to replicate selectively in certain human tumor cells (“SVV-permissive cells”), namely those that express TEM8, the receptor of SVV. SVV-001 is non-pathogenic in humans and animals. SVV-001 and the Seneca genus was originally discovered in 2001 at Novartis Pharmaceuticals by Dr. Paul Hallenbeck. SVV-001 was further developed as a novel cancer therapeutic at Neotropix, Inc. SVV-001 has been extensively tested in over 30 non-clinical cancer models, including immunotherapeutic settings, and in three clinical trials for various solid cancer namely neuroendocrine tumors such as carcinoids, small cell lung cancer and a variety of pediatric cancers. These trials confirmed the safety of intravenous dosing of SVV-001 and safety along with suggestions of significant clinical benefit. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

  • Voyager-V1: Vyriad, Inc.

VSV-IFNβ-NIS (Voyager V1; VV1) is derived from VSV, a bullet-shaped, negative-sense RNA virus with low human seroprevalence; it is engineered to replicate selectively in and kill human cancer cells. VV1 encodes hIFNβ to increase antitumoral immune response and tumor specificity, plus the thyroidal sodium iodide symporter NIS to allow imaging of virus. VV1 is synergistic with different anti-PD-(L)1 antibodies in several tumor models. Currently the drug is in Phase I/II stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

  • ADCT-701: ADC Therapeutics

ADCT-701 is an ADC composed of a humanized IgG1 antibody against human DLK-1, site-specifically conjugated using Glycoconnect technology to PL1601, which contains a valine-alanine cleavable linker and the PBD dimer cytotoxin SG3199. In vitro, ADCT-701 demonstrated potent cytotoxicity in a panel of human cancer cell lines of different origin and levels of DLK-1, while its potency was strongly reduced in DLK-1-negative cell lines. In vivo, ADCT-701 showed potent anti-tumor activity in the DLK1-expressing neuroblastoma-derived SK-N-FI xenograft in which a single dose of ADCT-701 at 0.5 or 1 mg/kg showed dose-dependent anti-tumor activity compared to the vehicle- and isotype control ADC-treated mice. Currently the drug is in Phase I stage of Clinical trial evaluation for the treatment of Neuroendocrine Tumors.

 

Explore groundbreaking therapies and clinical trials in the Neuroendocrine Tumors Pipeline. Access DelveInsight’s detailed report now! @ Neuroendocrine Tumors Treatment Drugs

 

Neuroendocrine Tumors Companies

Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene, Camurus, EpicentRx, RayzeBio, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Vyriad, Inc. and others.

 

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Intravenous
  • Subcutaneous
  • Oral
  • Intramuscular

 

Neuroendocrine Tumors Products have been categorized under various Molecule types such as

  • Monoclonal antibody
  • Small molecule
  • Peptide

 

Unveil the future of Neuroendocrine Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Neuroendocrine Tumors Market Drivers and Barriers

 

Scope of the Neuroendocrine Tumors Pipeline Report

  • Coverage- Global
  • Neuroendocrine Tumors Companies- Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene, Camurus, EpicentRx, RayzeBio, Inc., Shenzhen Chipscreen Biosciences Co., Ltd., Vyriad, Inc. and others.
  • Neuroendocrine Tumors Therapies- Ipilimumab, Nivolumab, Pembrolizumab, Niraparib, Apalutamide, Selpercatinib, Cabozantinib, Vandetanib, and others.
  • Neuroendocrine Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Neuroendocrine Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Neuroendocrine Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Neuroendocrine Tumors Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Neuroendocrine Tumors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Neuroendocrine Tumors– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. RYZ101: RayzeBio, Inc.
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SVV-001: Seneca Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ADCT-701: ADC Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Product Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Neuroendocrine Tumors Key Companies
  21. Neuroendocrine Tumors Key Products
  22. Neuroendocrine Tumors- Unmet Needs
  23. Neuroendocrine Tumors- Market Drivers and Barriers
  24. Neuroendocrine Tumors- Future Perspectives and Conclusion
  25. Neuroendocrine Tumors Analyst Views
  26. Neuroendocrine Tumors Key Companies
  27. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuroendocrine Tumors Pipeline 2024 | Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene

The US Electrical Contractors Market is Projected to Reach $256.65 Billion by 2029, Southern US Emerge as Prime Investment Hub – Arizton

“U.S. Electrical Contractors Market Research Report by Arizton”
Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

According to Arizton’s latest research report, the US electrical contractors market is growing at a CAGR of 1.29% during the forecast period.  

 

To Know More, Click: https://www.arizton.com/market-reports/us-electrical-contractors-market 

 

Report Summary  

Market Size (2029): USD 256.65 Billion 

Market Size (2023): USD 237.59 Billion 

CAGR (2023-2029): 1.29% 

Historic Year: 2020-2022  

Base Year: 2023  

Forecast Year: 2024-2029  

Market Segmentation: Services, Application, End-user, and Region 

 

Stay ahead of the curve with Arizton’s exclusive subscription plan, offering in-depth analysis, market sizing, and growth forecasts for less than $900 per month—a significant value compared to individual report purchases. Click here: https://www.arizton.com/subscription        

 

The growth in new construction or remodeling drives the demand for electrical contractors. The rise in 5G technology, demand from data centers, shift toward clean energy, and demand for EV charging infrastructure contribute to the growth of the US electrical contractors market. 

The growing adoption of AI and clean technology manufacturing significantly impacts the US electrical contractors market. This is mainly driven by the substantial energy requirements associated with AI technologies and the expansion of clean technology infrastructure, such as EVs and renewable energy sources. 

Moreover, the rapid expansion of AI has led to a surge in data center energy consumption. These centers, essential for training and operating AI models, require considerable computational power, significantly increasing electricity demand. In 2023, the North American Electric Reliability Corporation (NERC) reported that energy growth rates were at their highest since 2014, primarily due to increased electrification and the proliferation of EVs. This surge has prompted utilities and regulators to adapt quickly, creating opportunities for electrical contractors to implement advanced energy solutions to support the growing AI infrastructure​. 

 

Mergers & Acquisitions to Play a Major Role in the US Electrical Contractors Market 

The recent surge in mergers and acquisitions within the US electrical contractors market is fueled by several key factors and valuation considerations that enhance these companies’ appeal to investors. Companies offering competitive benefits and robust training programs are better equipped to retain a skilled workforce, making them attractive acquisition targets. Additionally, firms with strong market reputations benefit from referrals and recurring revenues, reducing customer acquisition costs and ensuring more predictable revenue streams, thereby boosting their overall valuation. 

Diversification of revenue streams also plays a pivotal role in driving M&A activity. Electrical contractors that have expanded their service portfolios to include recurring service work can stabilize income and lessen dependence on one-time project revenues. This diversification enhances resilience against market fluctuations and increases attractiveness to potential buyers. Furthermore, companies with a solid and expanding backlog, coupled with rising bid and win rates, demonstrate their ability to secure future projects and maintain business continuity. A healthy backlog signifies a consistent flow of future revenues, a crucial factor in M&A valuations. 

 

Buy this Research @ https://www.arizton.com/market-reports/us-electrical-contractors-market 

 

Regional Analysis  

South US consists of Texas, Florida, Virginia, Georgia, and others. This region witnesses a high demand for electrical contractors with colocation investments by many firms. 

Several vendors in this region invest in renewable energy as this region is one of the industrial hubs. For instance, Cinterra is at the forefront of America’s transition to utility-scale solar power, offering comprehensive solutions for constructing, distributing, and storing solar energy. As a nationwide full-lifecycle solar contractor, Cinterra brings unmatched expertise to every installation and construction phase. This includes electrical systems, energy storage, and substations, supported by a technology-enabled project management approach and a strong safety-first culture. 

 

Key Company Profiles 

  • Quanta Services 

  • MYR Group 

  • MDU Resources Group 

  • IES Holdings 

  • EMCOR 

  • MasTec 

  • ABM 

  • Aldridge 

  • American Electrical Contracting 

  • ArchKey Solutions 

  • Bergelectric 

  • Cache Valley Electric 

  • Cleveland Electric 

  • Collins Electrical Company 

  • Comfort Systems USA 

  • Commonwealth Electric Company 

  • Crete Mechanical Group (CMG) 

  • Cupertino Electric 

  • EC Electric 

  • E-J Electric Installation 

  • Facility Solutions Group 

  • Faith Technologies 

  • Five Star Electric 

  • Gaylor Electric 

  • Helix Electric 

  • Henkels & McCoy 

  • Hilscher-Clarke 

  • Hunt Electric 

  • Inglett & Stubbs 

  • J.F. Electric 

  • M.C. Dean 

  • Mid South Contractors 

  • Miller Electric Company 

  • MMR Group 

  • New England Electrical Contracting 

  • O’Connell Electric Company 

  • Power Design 

  • Redwood Electric Group 

  • RESA Power 

  • Rogers Electric 

  • Rosendin Electric 

  • SunGrid Solutions 

  • The Newtron Group 

  • Tri-City Electric 

  • Wachter 

  • Wayne J. Griffin Electric 

 

Market Segmentation 

Services 

  • Electrical 

  • Telecommunication 

  • Fire & Safety 

  • Electrical Control 

  • Highway 

  • Others 

Application 

  • New Construction 

  • Renovation or Maintenance 

End-use 

  • Outside 

  • Inside   

  • Residential 

  • Commercial 

  • Industrial 

  • Integrated Building System 

Region

The U.S. 

  • South 

  • West 

  • Midwest 

  • Northeast 

 

Check Out Some of the Top Selling Reports of Your Interest:     

U.S. Power Rental Market – Strategic Assessment & Forecast 2023-2029 

https://www.arizton.com/market-reports/united-states-power-rental-market 

Electric Vehicle Battery Recycling Market – Global Outlook & Forecast 2023-2028 

https://www.arizton.com/market-reports/electric-vehicle-battery-recycling-market 

 

Why Arizton?                                

100% Customer Satisfaction                                

24×7 availability – we are always there when you need us                                

200+ Fortune 500 Companies trust Arizton’s report                                

80% of our reports are exclusive and first in the industry                                

100% more data and analysis                                

1500+ reports published till date              

 

Post-Purchase Benefit                            

1hr of free analyst discussion                            

10% off on customization         

 

About Us:                                                                     

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                   

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                    

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                          

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707  
Country: United States
Website: https://www.arizton.com/market-reports/us-electrical-contractors-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The US Electrical Contractors Market is Projected to Reach $256.65 Billion by 2029, Southern US Emerge as Prime Investment Hub – Arizton

Gastrointestinal Stromal Tumors Pipeline 2024 | Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science

DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2024” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors (GIST) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Discover the latest drugs and treatment options in the Gastrointestinal Stromal Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Gastrointestinal Stromal Tumors Pipeline Outlook

 

Key Takeaways from the Gastrointestinal Stromal Tumors Pipeline Report

  • July 2024:- Deciphera Pharmaceuticals LLC- An International, Phase 3, Randomized, Multicenter, Open-label Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With KIT Exon 11 and Co-occurring KIT Exons 17 and/or 18 Mutations Who Were Previously Treated With Imatinib.
  • June 2024:- Merck Sharp & Dohme LLC– A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, Formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α Related Genetic Alterations.
  • DelveInsight’s Gastrointestinal Stromal Tumors Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline treatment therapies.
  • The leading Gastrointestinal Stromal Tumors Companies such as Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
  • Promising Gastrointestinal Stromal Tumors Therapies such as Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others.

 

Stay ahead with the most recent pipeline outlook for Gastrointestinal Stromal Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Gastrointestinal Stromal Tumors Approved Drugs

 

Gastrointestinal Stromal Tumors (GIST) Emerging Drugs

  • Famitinib: Jiangsu Hengrui Medicine

Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors (GIST).

  • Nilotinib: Novartis

Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors.

  • THE-630: Theseus Pharmaceuticals

THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST).

  • DS 6157: Daiichi Sankyo Company

DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo’s proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors.

 

Explore groundbreaking therapies and clinical trials in the Gastrointestinal Stromal Tumors Pipeline. Access DelveInsight’s detailed report now! @ Gastrointestinal Stromal Tumors Treatment Drugs

 

Gastrointestinal Stromal Tumors Companies

Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

 

Gastrointestinal Stromal Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.

 

Gastrointestinal Stromal Tumors Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Unveil the future of Gastrointestinal Stromal Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Gastrointestinal Stromal Tumors Market Drivers and Barriers

 

Scope of the Gastrointestinal Stromal Tumors Pipeline Report

  • Coverage- Global
  • Gastrointestinal Stromal Tumors Companies- Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, GlaxoSmithKline, Ascentage Pharma, Takeda, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.
  • Gastrointestinal Stromal Tumors Therapies- Belzutifan, Sunitinib, CGT9486, DCC-3116, Ripretinib, UCB4594, and others.
  • Gastrointestinal Stromal Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Gastrointestinal Stromal Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

 

Get the latest on Gastrointestinal Stromal Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Gastrointestinal Stromal Tumors Companies, Key Products and Unmet Needs

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Gastrointestinal Stromal Tumors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Gastrointestinal Stromal Tumors – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Famitinib: Jiangsu Hengrui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Nilotinib: Novartis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. DS 6157: Daiichi Sankyo Company
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Gastrointestinal Stromal Tumors Key Companies
  18. Gastrointestinal Stromal Tumors Key Products
  19. Gastrointestinal Stromal Tumors- Unmet Needs
  20. Gastrointestinal Stromal Tumors- Market Drivers and Barriers
  21. Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion
  22. Gastrointestinal Stromal Tumors Analyst Views
  23. Gastrointestinal Stromal Tumors Key Companies
  24. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Gastrointestinal Stromal Tumors Pipeline 2024 | Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, Chia Tai Tianqing Pharmaceutical Group, AB Science

The Outdoor Litter Vacuum Market to Reach $740.96 Billion by 2029 – Exclusive Research Report by Arizton

“Outdoor Litter Vacuum Market Research Report by Arizton”

According to Arizton’s latest research report, the outdoor litter vacuum market is growing at a CAGR of 4.32% during the forecast period.

 

To Know More, Click: https://www.arizton.com/market-reports/outdoor-litter-vacuum-market

 

Report Summary

Market Size (2029): USD 740.96 Billion

Market Size (2023): USD 575 Million

CAGR (2023-2029): 4.32%

Historic Year: 2020-2022

Base Year: 2023

Forecast Year: 2024-2029

Market Segmentation: Type, Power Source, Application, Commercial/Industrial, Distribution Channel, Geography

 

Stay ahead of the curve with Arizton’s exclusive subscription plan, offering in-depth analysis, market sizing, and growth forecasts for less than $900 per month—a significant value compared to individual report purchases. Click here:https://www.arizton.com/subscription      

 

The global demand for gardening and landscaping services is rising, driven by the growing popularity of aesthetic enhancements for residential and commercial spaces. Outdoor litter vacuums are crucial in maintaining these spaces and are increasingly used in both sectors. The residential market relies on these vacuums for garden and backyard upkeep, while the commercial sector, with larger budgets and extensive lawns, drives higher demand for these services. Additionally, rising construction activities, investments in public and private landscaping projects, and increased disposable incomes are fueling growth in the outdoor litter vacuum market. In the mature US landscaping industry, there is a shift towards comprehensive service offerings and innovative technologies aimed at improving efficiency and performance. Overall, the market is set to expand as companies focus on new technologies, better equipment, and enhanced service solutions for maintaining clean and attractive outdoor spaces.

Moreover, Li-ion technology particularly gained prominence for use in outdoor areas since it is eco-friendly, compact & lightweight, and eliminates the use of the cord. New technologies represent increased efficiency due to higher durability and quality in performance than traditional appliances, which could drive higher sales during the forecast period. The latest battery technology has been developed, which has faster charged and longer lifespans. These technologies enhance the performance of outdoor litter vacuums and increase their efficiency and effectiveness. Futuristic inventions in mainstream robotic technology and complementary technologies are expected to boost investor confidence in the market.

Consequently, the market will witness increased funding in the coming years. New start-ups will come up with outdoor litter vacuums with advanced features while existing vendors will continue to develop their product portfolio with upgrades. Thus, introducing upgrades is expected to fuel market growth during the forecast period. As the outdoor litter vacuum market presents lucrative revenue growth potential, many vendors are expected to enter the market during the forecast period, making it highly consolidated. Chinese manufacturers will expand their presence in Europe and North America, likely leading to a price war among vendors.

 

APAC Creating Investment Opportunities for Market Leaders

Outdoor litter vacuum manufacturers witness growth in Asia and customize their products to suit urban living environments, where compact spaces, parks, and quieter products are more in demand. Vendors in the market develop cost-effective models for price-sensitive customers in countries such as South Korea and India. Increasing cleaning efficiency and the demand for better warranties will drive rapid growth due to the rise in consumer awareness in the region. Japan and China, however, will focus on acquiring advanced and versatile machinery, whereas in markets such as South Korea and India, the more basic models with high efficiency will contribute to market growth. Cordless battery-powered litter vacuums are more prevalent in developed parts of the region but are expected to witness growth in other developing countries during the forecast period.

In the past decade, China has significantly increased landscaping efforts for outdoor spaces and yards. While many local landscaping enterprises exist due to low entry barriers, few hold top-tier qualifications in urban landscaping services. Government initiatives to expand municipal gardens have attracted numerous market players. The Chinese government is investing heavily in creating a greener environment and is actively promoting the construction of new gardens to combat rising pollution levels. Additionally, the government is focusing on implementing “green projects” that emphasize eco-friendly solutions, such as developing green buildings, establishing parks and gardens, and planting trees to enhance the landscape. These initiatives are expected to drive demand for outdoor litter vacuums, boosting market revenue in the region over the coming years.

 

Offline Distribution Channel to Boom in the Next 6 Years

In 2023, the offline distribution channel led the global outdoor litter vacuum market, accounting for 23.94% of the market share. This dominance is expected to continue due to the high customer preference for understanding the product’s functionalities and uses before purchase, especially given the high costs associated with outdoor litter vacuums. Traditional garden equipment manufacturers entering the market have boosted sales through offline channels like specialty stores and supermarkets, which provide personalized customer service. Educated staff in these stores help customers understand and select the right products. Although online sales are growing, specialty stores remain a significant distribution channel for outdoor litter vacuums.

Working in sync with dealers can create a positive brand influence among a larger audience. It is essential that market vendors partner with reputable dealers who have skilled mechanics. Vendors must encourage dealers to reduce turnaround time and maintain inventory levels. As demand grows and equipment distributors position themselves to capitalize on this growth, there is an increasing expansion of distributor facilities in developing regions such as APAC and the Middle East. Faster response time and enhanced customer service are crucial for market growth.

 

Buy this Research @ https://www.arizton.com/market-reports/outdoor-litter-vacuum-market

 

Vendors Insights

Stanley Black & Decker, Husqvarna Group, Robert Bosch, Nilfisk, & Makita are among the major vendors in the global outdoor litter vacuum market. The competition among these main players on the worldwide stage is high. Several players offer various gardening equipment to achieve economies of scale. Other players in the market are Exprolink, Elgee Vacs, Briggs & Stratton, and Ha-Ko Group. Most of the players followed the acquisition strategy to establish themselves as industry leaders. Market concentration is notable in developed countries like the US and Western European nations, whereas demand in emerging economies such as India is still emerging due to the influx of foreign brands. Competition among vendors primarily revolves around product offerings and pricing strategies. Leading market players focus on adopting energy-efficient products in response to the rising trend of using low-carbon energy sources. This shift addresses growing environmental concerns such as global warming and emissions from gasoline and exhaust. Manufacturers prioritize understanding diverse demand conditions while setting profitability goals and efficiently utilizing capital resources. The current landscape compels vendors to adapt and enhance their unique value propositions to maintain a robust market presence.

 

Key Company Profiles

  • Husqvarna Group
  • Makita
  • Nilfisk
  • Robert Bosch
  • Stanley Black & Decker
  • Applied Cleansing Solutions (ACS)
  • Briggs & Stratton
  • Cleva
  • Elgee Vacs
  • Exprolink (Madvac)
  • Greenworks Tools
  • Ha-Ko Group
  • Hako
  • Indcraft
  • Kärcher
  • Lifelong
  • Morclean
  • Overton UK
  • Positec Tool
  • Schiller Grounds
  • Snow Joe
  • STIHL
  • Trafalgar Cleaning Equipment

 

Market Segmentation

Type

  • Backpack/Hand-held Vacuum
  • Walk-behind Vacuum
  • Ride-on Vacuum

 

Power Source

  • Electric
  • Gas

 

Application

  • Commercial/Industrial
  • Residential

 

Commercial/Industrial

  • Landscaping & Property Management
  • Municipalities & Local Governments
  • Construction
  • Others

 

Distribution Channel

  • Offline
  • Online

 

Geography

  • North America
    • The US
    • Canada
  • Europe
    • Germany
    • The UK
    • France
    • Italy
    • Spain
    • Sweden
    • Netherlands
  • APAC
    • China
    • Japan
    • Australia
    • South Korea
    • India
    • Indonesia
    • Singapore
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East & Africa
    • Saudi Arabia
    • The UAE
    • South Africa

 

 

Check Out Some of the Top Selling Reports of Your Interest:   

Central Vacuum System Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/central-vacuum-system-market

Industrial Drain Cleaner Machine Market – Global Outlook & Forecast 2024-2029

https://www.arizton.com/market-reports/industrial-drain-cleaner-machine-market

 

Why Arizton?                              

100% Customer Satisfaction                              

24×7 availability – we are always there when you need us                              

200+ Fortune 500 Companies trust Arizton’s report                              

80% of our reports are exclusive and first in the industry                              

100% more data and analysis                              

1500+ reports published till date            

 

Post-Purchase Benefit                          

1hr of free analyst discussion                          

10% off on customization       

 

About Us:                                                                   

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                 

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                  

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                       

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707         
Country: United States
Website: https://www.arizton.com/market-reports/outdoor-litter-vacuum-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Outdoor Litter Vacuum Market to Reach $740.96 Billion by 2029 – Exclusive Research Report by Arizton

Celebrating two new books that keep the memory of Windrush alive

In the wake of Windrush Day celebrations, the rich cultural heritage and impactful contributions of the Windrush generation continue to resonate across the UK. It brings us great pleasure to announce two significant publications by Vivean V. Pomell: “Under the Mango Tree” and “Windrush Memoirs.” These books are dedicated to keeping the memory of Windrush alive and offer invaluable insights into this pivotal chapter of British history.

Vivean’s background further enriches the depth of her work. With over 30 years of experience in early childhood education, she is a former Ofsted inspector and holds both a BA and an MA in education. Her extensive experience and qualifications shine through in her writing, offering readers a profound understanding of the Windrush generation’s legacy.

“Under the Mango Tree” has garnered official recognition from the Legal Deposit Publications Request, highlighting its cultural and educational significance. These books are not just literary works; they are educational tools that can be used in schools, colleges, and libraries to teach future generations about the Windrush experience. Vivean’s personal history and dedication to education make her an authoritative voice in this field, providing readers with both factual knowledge and emotional depth.

In addition to these titles, she has authored and is in the process of publishing other educational books that she hopes will continue to inspire and educate. Her commitment to celebrating cultural diversity and heritage is evident in every page, making her works invaluable resources for anyone seeking to understand and appreciate the contributions of the Windrush generation.

Media Contact
Company Name: Learn with Lolonyo
Contact Person: Vivean V. Pomell
Email: Send Email
Country: United Kingdom
Website: https://www.amazon.co.uk/stores/page/517AF09B-12C1-4908-99B6-EA0B6120C730

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Celebrating two new books that keep the memory of Windrush alive

James Knight Drops New Single “Chill”

Rising R&B artist James Knight, known for his unique sound that seamlessly blends darker R&B tones with infectious melodies, is set to release his latest single, “Chill.” This new track is a testament to Knight’s evolving artistry and is sure to captivate both new listeners and longtime fans.

James Knight, born and raised in the vibrant city of Philadelphia, discovered his passion for singing at an early age. Hailing from a family with deep roots in the music industry, Knight was destined for musical greatness. From his preteen years, he performed on stages across the country, gaining recognition in various publications while also writing and composing for other artists—a testament to his multifaceted talent.

The hit-maker behind “Beautiful,” Knight has never been far from music, continually honing his craft and pushing the boundaries of his sound. His debut album, ‘Freedom of Sound,’ was met with critical acclaim, offering fans an intimate glimpse into his life through a versatile musical journey. This album showcased Knight’s ability to fuse innovative melodies with eclectic vibes, solidifying his place in the R&B genre.

“Chill” is the latest addition to Knight’s impressive repertoire. The single promises to deliver the same soulful depth and creativity that fans have come to expect. With its smooth rhythms and captivating lyrics, “Chill” is poised to be another hit in Knight’s growing discography.

James Knight’s recent musical prowess has attracted the attention of major labels, producers, engineers, and fellow musicians eager to collaborate. His upcoming projects are highly anticipated, with promises of new collaborations, tours, and music videos that will undoubtedly delight his audience.

Stay tuned for more updates on James Knight’s musical journey. “Chill” is now available on all major streaming platforms.

About James Knight

James Knight is an R&B singer and songwriter from Philadelphia. With a unique sound that blends darker R&B tones with catchy melodies, Knight has quickly become a notable figure in the music industry. His debut album, ‘Freedom of Sound,’ and hit single “Beautiful” have garnered widespread acclaim. Knight continues to captivate audiences with his innovative sound and soulful performances.

For more information, please contact: PR Knight.james1@gmail.com Follow James Knight; @JamesKnight

Media Contact
Company Name: James Knight
Contact Person: Media Relations
Email: Send Email
Country: United States
Website: https://www.instagram.com/jamesknightofficial

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: James Knight Drops New Single \”Chill\”